Alchemab Therapeutics

Executive Summary

Alchemab Therapeutics is a UK-based biotechnology company that leverages deep B cell sequencing and computational analysis to identify convergent protective antibody responses from resilient individuals such as long-term cancer survivors. Founded in 2019, the company has pioneered a platform to discover naturally occurring antibodies that may offer therapeutic benefits in hard-to-treat neurodegenerative diseases and oncology. By focusing on antibodies that the human immune system has already validated in resilient patients, Alchemab aims to reduce the risk of target failure and increase the probability of clinical success. The company is currently in Phase 1 development for lead programs targeting neurodegenerative disorders and oncology indications.

Upcoming Catalysts (preview)

• Q2 2027Phase 1 data readout for lead neurodegenerative program40% success
• Q4 2026Potential partnership or licensing deal for oncology program50% success
• Q1 2027Series B financing round to support pipeline advancement70% success